The role of memantine in the treatment of major depressive disorder: Clinical efficacy and mechanisms of action

Meysam Amidfar, Gislaine Z. Réus, Joao Quevedo, Yong Ku Kim

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

A developing body of evidence indicates that disturbed glutamate neurotransmission especially through N-methyl-d-aspartate (NMDA) is central to the pathophysiology of major depressive disorder (MDD) and NMDA receptor antagonists have shown therapeutic potential in the MDD treatment. Memantine is an uncompetitive NMDA receptor antagonist, approved for treatment of Alzheimer's disease (AD) that in contrast to other NMDA receptor antagonists at therapeutic doses does not induce highly undesirable side effects. Neuroprotective properties and well tolerability of memantine have been attributed to its unique pharmacological features such as moderate affinity, rapid blocking kinetics and strongly voltage-dependency. In this review we summarized clinical trial evidence of antidepressant effectiveness of memantine and its mechanisms of action. Available data indicate contradictory findings relating to clinical efficacy suggesting further research is necessary in determining as to whether memantine will eventually be an advantageous therapy for MDD. Preclinical data proposed various neurobiological mechanisms underlying antidepressant-like properties of memantine that are responsible for synaptic plasticity and cell survival.

Original languageEnglish
Pages (from-to)103-111
Number of pages9
JournalEuropean Journal of Pharmacology
Volume827
DOIs
Publication statusPublished - 2018 May 15

Fingerprint

Memantine
Major Depressive Disorder
Antidepressive Agents
Neuronal Plasticity
Aspartic Acid
Synaptic Transmission
Glutamic Acid
Cell Survival
Alzheimer Disease
Therapeutics
Clinical Trials
Pharmacology
Research
aspartic acid receptor

Keywords

  • Clinical efficacy
  • Major depressive disorder
  • Memantine
  • NMDA receptor

ASJC Scopus subject areas

  • Pharmacology

Cite this

The role of memantine in the treatment of major depressive disorder : Clinical efficacy and mechanisms of action. / Amidfar, Meysam; Réus, Gislaine Z.; Quevedo, Joao; Kim, Yong Ku.

In: European Journal of Pharmacology, Vol. 827, 15.05.2018, p. 103-111.

Research output: Contribution to journalReview article

@article{09f1ebf8620e4c34ba1c1f91be048ff0,
title = "The role of memantine in the treatment of major depressive disorder: Clinical efficacy and mechanisms of action",
abstract = "A developing body of evidence indicates that disturbed glutamate neurotransmission especially through N-methyl-d-aspartate (NMDA) is central to the pathophysiology of major depressive disorder (MDD) and NMDA receptor antagonists have shown therapeutic potential in the MDD treatment. Memantine is an uncompetitive NMDA receptor antagonist, approved for treatment of Alzheimer's disease (AD) that in contrast to other NMDA receptor antagonists at therapeutic doses does not induce highly undesirable side effects. Neuroprotective properties and well tolerability of memantine have been attributed to its unique pharmacological features such as moderate affinity, rapid blocking kinetics and strongly voltage-dependency. In this review we summarized clinical trial evidence of antidepressant effectiveness of memantine and its mechanisms of action. Available data indicate contradictory findings relating to clinical efficacy suggesting further research is necessary in determining as to whether memantine will eventually be an advantageous therapy for MDD. Preclinical data proposed various neurobiological mechanisms underlying antidepressant-like properties of memantine that are responsible for synaptic plasticity and cell survival.",
keywords = "Clinical efficacy, Major depressive disorder, Memantine, NMDA receptor",
author = "Meysam Amidfar and R{\'e}us, {Gislaine Z.} and Joao Quevedo and Kim, {Yong Ku}",
year = "2018",
month = "5",
day = "15",
doi = "10.1016/j.ejphar.2018.03.023",
language = "English",
volume = "827",
pages = "103--111",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",

}

TY - JOUR

T1 - The role of memantine in the treatment of major depressive disorder

T2 - Clinical efficacy and mechanisms of action

AU - Amidfar, Meysam

AU - Réus, Gislaine Z.

AU - Quevedo, Joao

AU - Kim, Yong Ku

PY - 2018/5/15

Y1 - 2018/5/15

N2 - A developing body of evidence indicates that disturbed glutamate neurotransmission especially through N-methyl-d-aspartate (NMDA) is central to the pathophysiology of major depressive disorder (MDD) and NMDA receptor antagonists have shown therapeutic potential in the MDD treatment. Memantine is an uncompetitive NMDA receptor antagonist, approved for treatment of Alzheimer's disease (AD) that in contrast to other NMDA receptor antagonists at therapeutic doses does not induce highly undesirable side effects. Neuroprotective properties and well tolerability of memantine have been attributed to its unique pharmacological features such as moderate affinity, rapid blocking kinetics and strongly voltage-dependency. In this review we summarized clinical trial evidence of antidepressant effectiveness of memantine and its mechanisms of action. Available data indicate contradictory findings relating to clinical efficacy suggesting further research is necessary in determining as to whether memantine will eventually be an advantageous therapy for MDD. Preclinical data proposed various neurobiological mechanisms underlying antidepressant-like properties of memantine that are responsible for synaptic plasticity and cell survival.

AB - A developing body of evidence indicates that disturbed glutamate neurotransmission especially through N-methyl-d-aspartate (NMDA) is central to the pathophysiology of major depressive disorder (MDD) and NMDA receptor antagonists have shown therapeutic potential in the MDD treatment. Memantine is an uncompetitive NMDA receptor antagonist, approved for treatment of Alzheimer's disease (AD) that in contrast to other NMDA receptor antagonists at therapeutic doses does not induce highly undesirable side effects. Neuroprotective properties and well tolerability of memantine have been attributed to its unique pharmacological features such as moderate affinity, rapid blocking kinetics and strongly voltage-dependency. In this review we summarized clinical trial evidence of antidepressant effectiveness of memantine and its mechanisms of action. Available data indicate contradictory findings relating to clinical efficacy suggesting further research is necessary in determining as to whether memantine will eventually be an advantageous therapy for MDD. Preclinical data proposed various neurobiological mechanisms underlying antidepressant-like properties of memantine that are responsible for synaptic plasticity and cell survival.

KW - Clinical efficacy

KW - Major depressive disorder

KW - Memantine

KW - NMDA receptor

UR - http://www.scopus.com/inward/record.url?scp=85044040751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044040751&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2018.03.023

DO - 10.1016/j.ejphar.2018.03.023

M3 - Review article

C2 - 29551658

AN - SCOPUS:85044040751

VL - 827

SP - 103

EP - 111

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

ER -